“This acquisition will propel us into a solid position of leadership in CBD product formulation standardization and quality assurance of hemp-based medicinal CBD products,” said Frank Igwealor, Cannabionoid Biosciences’ CFO. “With our vision of building a completely vertically integrated CBD operation model, ensuring quality and premium status of product in our distribution is paramount.“ This acquisitions will also be accretive to our earnings immediately as follows:
Total Acquisition Cost: $33,430,000 Fixed Assets Acquired: $18,850,000 Total Projected Revenue: $30,257,162 Estimated Net Profit: $9,322,460
Cannabinoid Biosciences (“CBDZ”) has reserved September 28, 2019 for the official launch of its crowdfunding campaign to raise $50 million under Regulation A+